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ABSTRACT
Objective: To compare flucloxacillin with clindamycin
to flucloxacillin alone for the treatment of limb
cellulitis.
Design: Parallel, double-blinded, randomised
controlled trial.
Setting: Emergency department attendances and
general practice referrals within 20 hospitals in
England.
Interventions: Flucloxacillin, at a minimum of 500 mg
4 times per day for 5 days, with clindamycin 300 mg 4
times per day for 2 days given orally versus
flucloxacillin given alone.
Main outcome measures: The primary outcome was
improvement at day 5. This was defined as being
afebrile with either a reduction in affected skin surface
temperature or a reduction in the circumference of the
affected area. Secondary outcomes included resolution
of systemic features, resolution of inflammatory
markers, recovery of renal function, reduction in the
affected area, decrease in pain, return to work or normal
activities and the absence of increased side effects.
Results: 410 patients were included in the trial. No
significant difference was seen in improvement at day 5
for flucloxacillin with clindamycin (136/156, 87%)
versus flucloxacillin alone (140/172, 81%)—OR 1.55
(95% CI 0.81 to 3.01), p=0.174. There was a significant
difference in the number of patients with diarrhoea at
day 5 in the flucloxacillin with clindamycin allocation
(34/160, 22%) versus flucloxacillin alone (16/176, 9%)
—OR 2.7 (95% CI 1.41 to 5.07), p=0.002. There was
no clinically significant difference in any secondary
outcome measures. There was no significant difference
in the number of patients stating that they had returned
to normal activities at the day 30 interview in the
flucloxacillin with clindamycin allocation (99/121, 82%)
versus flucloxacillin alone (104/129, 81%)—adjusted
OR 0.90 (95% CI 0.44 to 1.84).
Conclusions: The addition of a short course of
clindamycin to flucloxacillin early on in limb cellulitis
does not improve outcome. The addition of clindamycin
doubles the likelihood of diarrhoea within the first few
days.
Trial registration number: NCT01876628, Results.
INTRODUCTION
Cellulitis is a common acute skin infection
occurring anywhere on the body, which
causes pain, swelling and erythema. It
cannot be reliably distinguished from erysip-
elas which may be considered a form of cel-
lulitis.1 Cellulitis may be accompanied by
fever and other systemic features. A UK study
in 19922 estimated a cellulitis incidence rate
of 16.4 per 1000 person-years in patients pre-
senting to general practice. In England alone
during 2012, people admitted with a diagno-
sis of cellulitis took up 400 000 bed days.3
Microbiological studies are positive in a
variable proportion of people who present to
hospital with erysipelas or cellulitis. The use
of latex agglutination techniques and direct
immunoﬂuorescence on skin biopsy speci-
mens increases the yield and has shown that
β haemolytic streptococci, usually group A
streptococci (GAS) or group G, represent
the most prominent bacteria in studies of cel-
lulitis and erysipelas, accounting for almost
80% of isolated organisms.4 5 Molecular
testing6 and serology7 have been found to be
of variable value but can improve the yield,
especially if the patient has received antibio-
tics.8 It is probable that Staphylococcus aureus
is not the causative agent in most cases
Strengths and limitations of this study
▪ This was a double-blind randomised multicentre
study and the first to examine the effect of
adjunctive clindamycin with β-lactam therapy for
cellulitis.
▪ Patients were recruited from general practice,
emergency department patients and inpatients
and are thus a representative population.
▪ The study lost 18% of the patients by the first
follow-up visit but the characteristics of these
patients were similar in both drug allocations.
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where it was isolated, adopting an opportunistic
bystander role. This is supported by a study which
demonstrated no extra beneﬁt when adding an anti-
biotic active against meticillin-resistant S. aureus (MRSA)
in the presence of MRSA carriage.9
Standard therapy is with a β-lactam antibiotic, com-
monly ﬂucloxacillin or a cefalosporin, which, while effect-
ive,10 often leaves the patient with signiﬁcant skin
damage which takes many weeks to heal. β-lactams need a
growing or dividing bacterium in order to work.
Clindamycin, a protein-inhibiting antibiotic, inhibits
toxin production and is able to kill intracellular strepto-
cocci.11 12 It is these toxins which are responsible for
local damage and systemic features.13 Protein-inhibiting
antibiotics are part of recommended therapy for invasive
GAS infections such as necrotising fasciitis and pleural
empyema, but there is conﬂicting evidence of any
beneﬁt14 15 and there are no clinical trials to support it.
The evidence for an effect in reducing toxin has been
predominantly in vitro and even in vitro studies show
antagonism under some conditions,16 but one retrospect-
ive and one prospective review showed the beneﬁt of clin-
damycin in invasive infections caused by GAS.17 18
Clindamycin is a recommended treatment for cellulitis
in the British National Formulary;19 it is a lincosamide
and is also active against some macrolide (eg, clarithro-
mycin) resistant strains of streptococci and staphylococci.
It was the second most common treatment for cellulitis in
a survey of Canadian hospitals20 and clindamycin or clari-
thromycin featured in every 1 of 23 guidelines examined
as part of a review of treatment of cellulitis in the south
west of England.21 If clindamycin is an effective adjuvant
in serious streptococcal infections, its beneﬁt should be
detectable in cellulitis. A reduction in toxin production
should lead to a reduction in the severity of infection and
result in less pain, more rapid resolution, improved short-
term health-related quality of life and a more rapid
return to normal activity.
This trial was designed to determine whether clinda-
mycin has an additional beneﬁcial effect in cellulitis.
Clear evidence that clindamycin has no beneﬁt would
have implications for the use of it as adjunctive or
sequential therapy in cellulitis. Failure to demonstrate
beneﬁt would also suggest that the present recommen-
dations for its use in invasive GAS infections need to be
re-evaluated.
METHODS
Trial design and participants
We conducted a double-blind, randomised, placebo-
controlled trial from October 2013 to December 2015,
with 1:1 parallel group allocation. Potential participants
were screened from emergency departments, hospital
inpatients and referrals to hospital from general practice
(family physicians) from 20 hospitals in England.
The diagnosis of cellulitis was supported using a set of
criteria established for the PATCH trials on the prevention
of recurrent cellulitis.22 All adult patients with unilateral
limb cellulitis were eligible; the key exclusion criteria were
antibiotic treatment for longer than 48 hours, previous
Clostridium difﬁcile infection, past MRSA carriage, allergy
to either penicillin or clindamycin (self-reported or from
their medical records) and pre-existing diarrhoea.
Patients with obvious abscesses were not eligible. We col-
lected data on randomised and non-randomised partici-
pants as speciﬁed by CONSORT (ﬁgure 1).
All participants were given ﬂucloxacillin orally or intra-
venously, and the dose and route were decided by the
clinical team treating the patient. The minimum dose
and duration of ﬂucloxacillin speciﬁed in the protocol
was 500 mg four times per day orally for 5 days.
Participants on other β-lactams prior to recruitment, for
example, co-amoxiclav, were switched to ﬂucloxacillin.
The dose of clindamycin in this trial was 300 mg four
times per day orally, which has been used in a large trial
of skin and soft tissue infections,23 and the duration was
2 days. The duration was designed to achieve adequate
tissue levels of clindamycin while minimising the side
effects. The protocol speciﬁed that clindamycin or
placebo was to be started within 48 hours of starting the
β-lactam. This period was a compromise between giving
the patient adequate time to consider the trial and min-
imise the duration of any preceding β-lactam antibiotic,
which might reduce any effect of clindamycin.
Randomisation and blinding
Randomisation was web-based with blocks of eight and
stratiﬁed by age (<65 and >64) and part of the week to
allow for variation in follow-up caused by weekends. The
randomisation system provided a study number and
study drug bottle number. Study medication was pre-
pared and dispensed by the University Hospitals Bristol
Pharmacy which provided batches of the medication
bottles to the study sites. Both clindamycin and placebo
were formulated and supplied in identical capsules
sealed in identical medication bottles. Only the phar-
macy kept the code of whether the bottle contained clin-
damycin or placebo. The pharmacy had no access to the
clinical data or patient identiﬁcation unless unblinding
was required. The study nurses, the statistician, and all
investigators and participants were blind to whether the
bottle contained clindamycin or placebo.
Procedures
The study schedule consisted of three face-to-face visits,
at baseline, days 5 and 10, with a telephone follow-up at
day 30. At the ﬁrst three visits, we measured standard
observations (temperature, pulse, blood pressure and
respiration rate). We also took blood for a full blood
count, renal function, C reactive protein and albumin.
We estimated the affected skin area of the limb using a
scoring system similar to that used in psoriasis24 from
which we calculated the percentage of body skin area.
We measured the limb circumference at its greatest over
the affected area and the highest temperature from the
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affected area and took comparable measurements from
the unaffected limb, if available. The temperature mea-
surements were made with an infrared thermometer,25
limb circumference with a disposable tape measure and
pain scores were measured using a visual analogue scale.
A record of adverse events was made at each visit. The
actual number of days after randomisation on which
follow-up occurred was variable. The day of follow-up
was dependent on the patients’ circumstances and,
rather than lose a patient to follow-up, we asked patients
to attend whenever they could, while still maintaining
the target of 4 days post randomisation. We asked
patients to return the study drug containers and
counted the remaining capsules.
We collected additional information, including Euroqol
(EQ-5D-5L) and Health Today scores, at baseline and day
30 for a health economics analysis. We asked patients at
each visit and at the day 30 telephone follow-up whether
or not they considered themselves to be back to their
normal activities. At baseline, we recorded the time
between the onset of systemic features, if reported, and
local features. We recorded the time that antibiotics were
ﬁrst taken. We asked the patients about previous surgery,
trauma or cellulitis of the affected limb and whether they
had been diagnosed as having lymphoedema or diabetes
mellitus as these are recognised risk factors.26
Outcomes
The primary outcome was improvement at the day 5
follow-up visit. This was deﬁned in the protocol as being
afebrile (<37.5°C) and either having a reduction in limb
swelling (measured by limb circumference) or a
Figure 1 Flow chart summarising the numbers of patients screened for eligibility and numbers present at each follow-up.
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reduction in erythema (measured by skin surface tem-
perature) of 0.2 SDs or more for both local measure-
ments. The reduction in limb swelling and limb
temperature was determined using the difference
between affected and unaffected limbs to reduce con-
founding by ambient temperature, clothing and posture.
These three clinical features were chosen because they
could be measured accurately. Secondary outcomes
included resolution of systemic features, resolution of
inﬂammatory markers, recovery of renal function, reduc-
tion in the affected area, decrease in pain, return to
work or normal activities and the absence of increased
side effects.
Statistics
The estimated number improving in the placebo group
at ﬁrst follow-up was 80%. A two-group continuity-
corrected χ2 test with a 0.05 two-sided signiﬁcance level
will have an 80% power to detect the difference between
80% improving in the placebo group and 90% improv-
ing in the clindamycin group (OR of 2.250) when the
sample size with complete data in each group is 219
(total 438). We were not able to make any estimates of
the recruitment rate and likely losses to follow-up as
there was no suitable source of data; the only UK trial of
cellulitis in an emergency department (the primary
source of patients for this study) was reported in 2005
and used parenteral antibiotics.27
Conﬁrmation of the determination of the primary
outcome was made by the Trial Steering Group during
the trial. There was no interim analysis and there were
no prespeciﬁed subgroup analyses. The decision to
undertake subgroup analyses was made after the analysis
of the primary outcome. The trial was stopped at
26 months, with 410 patients randomised, for funding
reasons.
Data were analysed on an intention-to-treat (ITT)
basis. Fisher’s exact test, with ORs, was used to deter-
mine whether there was a difference in those improving
in each group at ﬁrst follow-up (day 5). The analysis of
the secondary outcomes adjusted for some baseline
imbalances between the treatment allocations (namely
baseline total affected area, difference between baseline
affected and unaffected limb temperature, difference
between baseline affected and unaffected limb circum-
ferences and the logarithm of neutrophil count). The
analysis of the primary outcome was also repeated,
adjusting for these factors. Continuous outcomes were
analysed using analysis of covariance (ANCOVA) and
also adjusted for the baseline value of the outcome as
well as the baseline imbalances. For dichotomous out-
comes, logistic regression analysis was used to compare
the adjusted odds of the outcome by treatment group.
For continuous outcomes, there were some occasions
where the distribution of the data was such that the loga-
rithm of the outcome was used in the ANCOVA, and
there were also a few occasions when the assumptions
for the ANCOVA were not met, so it was necessary to use
a Mann-Whitney test to compare the allocations.
Medians have been reported instead of means where the
data are markedly skewed.
PATIENT INVOLVEMENT
Patients were not involved in designing the study apart
from the patient information sheet. We used qualitative
study data collected previously, which highlighted
patient comfort as important, to inform the choice of
outcomes.28 29 The day 30 telephone consultation asked
for feedback and comments on the conduct of the
study. Towards the end of the study, we arranged a
meeting and an online survey focusing on patients’
symptoms and non-pharmacological interventions.
RESULTS
Baseline
In total, 2444 patients with a diagnosis of cellulitis were
screened for eligibility. Four hundred and ten patients
were randomised, ranging from 18 to 95 years. Nine
patients were subsequently found to be ineligible
because they had received more than 48 hours of anti-
biotics (ﬁve patients) or the diagnosis was incorrect
(four patients). The ﬂow chart (ﬁgure 1) summarises
the numbers of patients screened for eligibility and
numbers present at each follow-up. All patients rando-
mised are included in the ITT population. The baseline
characteristics of the randomised patients are sum-
marised in table 1; not every patient had a complete set
of baseline data. The clindamycin allocation patients
were slightly younger and had less severe cellulitis.
Overall, 55 (13%) patients had a history of previous
surgery, 63 (15%) of trauma to and 132 (32%) of cellu-
litis of the affected limb. Nineteen (5%) had a diagnosis
of lymphoedema and 36 (9%) of diabetes mellitus.
Withdrawal from the study and non-attendance at day 5
Overall, 48 patients were actively withdrawn from the
study, either at their own request or their physician’s: 27
in the clindamycin allocation and 21 in the placebo
allocation.
Six patients were found to be ineligible immediately
after randomisation and did not receive the study drug
(ﬁve clindamycin and one placebo). The most common
reason for active withdrawal from the study was that the
patient was given open-label clindamycin either uninten-
tionally (4 patients) or intentionally (14 patients), 9 in
each allocation. One of these patients was unblinded,
the only one from the trial, at the request of the clinical
team. Four patients had the diagnosis changed, three in
the clindamycin allocation. Three patients were with-
drawn because of an adverse event, one in the clindamy-
cin allocation. Eleven patients withdrew their consent,
eight in the clindamycin allocation. Seven patients with-
drew for other reasons, three in the clindamycin alloca-
tion. Four patients given open-label clindamycin before
day 5 are included in the analysis of primary outcome:
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two in the clindamycin allocation and two in the
placebo allocation.
We looked at the baseline characteristics of those
patients who did not attend the day 5 follow-up and
compared them with those who did by univariate ana-
lysis. We found that the non-attendees, as a group, were
signiﬁcantly younger; the mean age of attendees was
50.8 and that of non-attendees was 41.4 years (p<0.001)
Attendees were signiﬁcantly more likely to have leg cel-
lulitis than non-attendees: 76% vs 62% (p=0.02).
Attendees were less likely to have a systemic inﬂamma-
tory response syndrome (SIRS) score ≥1; 41% vs 59% of
non-attendees (p=0.006). There were no differences in
the baseline characteristics of the non-attendees
between the study drug allocations.
Primary outcome and day 5 follow-up
We were able to calculate the primary outcome for 328
patients. To be evaluable, patients had to have a body
temperature measurement and a measurement of either
limb circumference or limb surface temperature. Those
with missing data on temperature at day 5, or the three
with missing unaffected limb data, were categorised as
having missing data for primary outcome. Patients with
temperature data, but with missing data on both limb
circumference and limb temperature, were categorised
as not improved, rather than missing. Patients with tem-
perature data, and with either a measure for change in
circumference or change in limb temperature, were
categorised according to the two out of three data items
they had available. The median number of days to
follow-up was 4.0 for clindamycin and 4.1 for placebo.
Within the evaluable population, there was no signiﬁ-
cant difference in improvement which was 87% for clin-
damycin and 81% for placebo; OR 1.55 (95% CI 0.81 to
3.01), p=0.17 (table 2). Adjusting for baseline differ-
ences did not alter the primary outcome result. As a pro-
portion of those patients randomised improvement
occurred in 67% of those on clindamycin compared
with 68% of those on placebo; OR 0.97 (95% CI 0.63 to
1.50), p=0.92.
Route, dose and duration of flucloxacillin
The quality of the data on the duration and route of ﬂu-
cloxacillin during the trial was poor. We had not set out
to collect data on dose because we assumed a standard
dose of oral ﬂucloxacillin, but we later discovered that
some hospitals used higher doses. Consequently, we have
not included this in any of the analyses presented here.
Subgroup analyses
We did not specify any subgroup analysis in the study
protocol but in order to clarify whether there might
have been a positive effect from clindamycin in a subpo-
pulation and a negative, or neutral effect, in another
subpopulation, we undertook subgroup analyses. We
Table 1 Baseline characteristics of the randomised patients
Clindamycin
(n=203)
Placebo
(n=207)
Mean (SD) age in years 47.7 (18.4) 50.5 (16.9)
Male 129 (64) 149 (72)
Leg affected 150 (74) 149 (72)
Duration of local features before starting study drug (days); median (IQR) 2.1 (2.1) 2.0 (2.1)
Duration of preceding antibiotics before starting study drug (hours); median (IQR) 1.9 (19.0) 6.5 (23.5)
Temperature (°C); mean (SD) 36.8 (0.5) 36.9 (0.7)
Pulse (bpm); mean (SD) 81 (15) 81 (14)
Systolic blood pressure (mm Hg); mean (SD) 131 (20) 128 (18)
Affected skin area as percentage of body surface area; median and IQR 4 (4) 4 (6)
Difference in circumference between affected and unaffected limb (cm); mean (SD) 2.5 (2.1) 2.9 (2.1)
Difference in surface temperature between affected and unaffected limb (°C);
mean (SD)
2.5 (1.9) 2.7 (1.6)
Neutrophil (×109/L); median (IQR) 6.3 (4.6) 7.0 (4.9)
Lymphocyte (×109/L); median (IQR) 1.6 (0.7) 1.5 (1.1)
Urea (mmol/L); median (IQR) 5.0 (2.1) 4.9 (2.1)
Albumin (g/L); median (IQR) 39 (7) 38 (8)
C reactive protein (mg/L); median (IQR) 23 (80) 54 (119)
Pain score (VAS); median (IQR) 5 (4) 5 (4)
SIRS score ≥1* 83/200 (42) 96/207 (46)
Figures are numbers of patients (percentage) unless otherwise stated.
Not every patient had every characteristic recorded.
One per cent of the total body skin area is ∼170 cm2; 10% of the total body skin area is approximately equal to the area of one arm or half the
area of a leg.
*SIRS criteria: one point each for temperature <36°C or >38°C, pulse >90, respiratory rate >20, WCC<4 or >12×109/L (WCC count derived
from neutrophils plus lymphocytes plus 1).
SIRS, systemic inflammatory response syndrome; VAS, visual analogue scale; WCC, white cell count.
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looked at severity as deﬁned as having a SIRS score of 0
or more than 0; duration of local features (area, skin
temperature and swelling) of between 48 and 84 hours,
or <48 hours prior to randomisation; duration of antibio-
tics prior to the study drug of >12 or <12 hours. No stat-
istically signiﬁcant difference in improvement in any
subgroup was found.
Compliance
The majority of the study drugs were taken; 148/159
(93%) in the clindamycin group and 159/176 (90%) of
the placebo group had zero capsules remaining. The
mean number of capsules remaining of the 11/159 in
the clindamycin allocation was 6.5 and of the 17/176 in
the placebo allocation was 4.4 out of 16 capsules.
Day 10 follow-up and secondary outcomes
Fifty-four patients who attended at day 5 did not attend
at day 10. The non-attendees were younger but other-
wise similar to those who attended day 5. There was no
signiﬁcant difference in any secondary outcome mea-
sures except a slightly lower mean blood pressure (sys-
tolic, 3 mm Hg) in the clindamycin allocation at day 10
and lower median lymphocyte counts in the clindamycin
allocation at both days 5 and 10 (0.18 and 0.19×109/L,
respectively). The median number of days to follow-up
was 9 in both allocations. Table 3 summarises the sec-
ondary outcomes at days 5 and 10.
Back to normal activities
At day 5, 76/158 (48%) of the clindamycin allocation
were back to normal activities compared with 74/175
(42%) of the placebo allocation (OR 1.09 (CI 0.66 to
1.78), p=0.74). At day 10, 77/133 (58%) of the clinda-
mycin allocation were back to normal activities com-
pared with 82/153 (54%) of the placebo allocation (OR
1.13 (CI 0.67 to 1.89), p=0.65). At the day 30 follow-up,
the median duration from recruitment was 38.4 days in
both allocations. Two hundred and ﬁfty patients had a
response to the question on their return to normal activ-
ities; 99/121 (82%) in the clindamycin allocation were
back to normal activities compared with 104/129 (81%)
in the placebo allocation (OR 0.90 (95% CI 0.44 to
1.84), p=0.77). The ORs are adjusted ORs adjusting for
total affected area, difference in limb circumference, dif-
ference in limb temperature and neutrophil at baseline.
Adverse events
Diarrhoea was the most common adverse event in the
clindamycin allocation with 34/158 (22%) of the clinda-
mycin allocation reporting it compared with 16/172
(9%) in the placebo allocation (OR 2.7 (95% CI 1.41 to
5.07), p=0.002; table 4). Adverse events resulted in three
patients leaving the trial before day 5. Any hospital
admission, for any reason, after recruitment and during
the ﬁrst 10 days of follow-up was recorded as a serious
adverse event (SAE). There were 23 SAE (8 in the clin-
damycin allocation and 15 in the placebo allocation)
and none were thought to be related to their study drug
treatment. No case of C. difﬁcile infection was reported.
Two patients died before day 30 of causes unrelated to
cellulitis or their treatment (one myocardial infarction
and one pulmonary embolus), both of whom were in
the placebo allocation.
DISCUSSION
The results of this clinical trial do not provide evidence
that any feature of cellulitis was improved by the add-
ition of clindamycin. We collected a wide array of object-
ive data in order to detect particular effects of
clindamycin which might be related to toxin production
and none showed any effect. The range of severity in
the study patients was wide; we included those both on
oral and intravenous ﬂucloxacillin therapy. We looked to
see whether clindamycin’s effects may be only evident in
those with more severe disease, in those who had a
shorter duration of features or in those who had anti-
biotic treatment earlier. We could ﬁnd no evidence that
any of these circumstances made the addition of clinda-
mycin beneﬁcial. However, we did ﬁnd that the propor-
tion of patients in the clindamycin allocation with
diarrhoea, up to day 5, was double that of the patients
receiving placebo.
This study has some weaknesses; about 20% of patients
did not attend the ﬁrst follow-up but this is a feature of
an acute infection which, in many people, heals rapidly,
and of the population attending emergency depart-
ments. We were unable to ﬁnd any signiﬁcant
Table 2 Primary outcome
Clindamycin
(n=203)
Placebo
(n=207)
Insufficient day 5 data* 47 35
Not improved 20 32
Improved, as a proportion of those evaluable 136/156 (87) 140/172 (81) OR 1.55 (95% CI 0.81 to 3.01)
p=0.17
Improved, as a proportion of the randomised
population
136/203 (67) 140/207 (68) OR 0.97 (95% CI 0.63 to 1.50)
p=0.92
Figures are numbers of patients (percentage).
*Either did not attend follow-up or were missing data.
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differences in attendance between the two study alloca-
tions that could not be accounted for by the marginal
differences in severity. We were unsure of what duration
we should allow between initial antibiotic therapy and
clindamycin but we could ﬁnd no signiﬁcant difference
in outcome when we compared those having started
antibiotics within 12 hours with those between 12 and
48 hours. We were also uncertain about the appropriate
duration of clindamycin to detect an effect if it was
present. We did detect an effect, an adverse one, diar-
rhoea, within the 48-hour duration.
This study was developed as a result of a south west
England regional review of treatment of proven GAS
infection which was undertaken in 2011. As part of this
review, we could ﬁnd no evidence of beneﬁt of the add-
ition of clindamycin despite its widespread and increas-
ing use. This led us to look at a way of testing the
hypothesis that clindamycin’s protein-inhibiting activity
is of beneﬁt in GAS infection. There had been no previ-
ous studies on adjunctive clindamycin in cellulitis and
we thought this study would be helpful in the manage-
ment of cellulitis and invasive GAS infections. This study
was designed to test the hypothesis that a
toxin-inhibiting antibiotic, of which clindamycin is the
exemplar, is effective in streptococcal infections.
Cellulitis is a common streptococcal infection with
easy-to-measure objective features and has been used in
this trial as a representative streptococcal infection. We
think it is reasonable to generalise the results of this trial
to other streptococcal infections in the absence of spe-
ciﬁc trials.
The in vitro evidence that supported clindamycin’s
beneﬁts is conﬂicting and the clinical evidence of
beneﬁt in invasive GAS infections has the biases intrinsic
in these retrospective and prospective studies:17 18
patient selection, patient treatment, recall and
Table 3 Secondary outcomes
Time point Clindamycin Placebo p Value
Temperature (°C); mean
Baseline 36.8 36.9
Day 5 36.6 36.5 0.07
Day 10 36.5 36.5 0.74
Pulse (bpm); mean
Baseline 80 80
Day 5 78 76 0.20
Day 10 78 77 0.76
Systolic blood pressure (mm Hg); mean
Baseline 131 129
Day 5 129 131 0.19
Day 10 128 131 0.02
Affected skin area as percentage of body surface area;
median
Baseline 4 5
Day 5 2 2 0.28
Day 10 1 1 0.67
Difference in circumference between affected and
unaffected limb (cm); mean
Baseline 2.67 2.84
Day 5 2.04 2.18 0.74
Day 10 1.42 1.77 0.90
Difference in surface temperature between affected and
unaffected limb (°C); mean
Baseline 2.49 2.67
Day 5 1.15 1.57 0.24
Day 10 0.87 1.13 0.65
Neutrophil (×109/L); median
Baseline 5.97 6.95
Day 5 4.24 4.43 0.95
Day 10 4.18 4.32 0.86
Lymphocyte (×109/L); median
Baseline 1.51 1.50
Day 5 1.70 1.88 0.01
Day 10 1.75 1.94 0.01
Urea (mmol/L); median
Baseline 5.0 4.9
Day 5 4.8 5.0 0.09
Day 10 4.9 5.2 0.37
Albumin (g/L); median
Baseline 38 38
Day 5 38 37 0.82
Day 10 39 38 0.63
C reactive protein (mg/L); median
Baseline 22 57
Day 5 10 16 0.43
Day 10 5 6 0.20
Pain score (VAS); median
Baseline 4.5 5
Day 5 2 2 0.30
Day 10 0 1 0.61
Figures are values at each time point (means or medians).
The baseline values are of those patients who attended day
5. The baseline values for those attending day 10 are similar to
the day 5 baseline values.
All p values are from ANCOVA (adjusted for baseline) except for
pain VAS score at day 5 (Mann-Whitney U test).
ANCOVA, analysis of covariance; VAS, visual analogue scale.
Table 4 Adverse events or reactions
Clindamycin Placebo p Value
Reported at day 5 n=160 n=176
Rash 3 (1.9) 8 (4.6) 0.22
Diarrhoea 34 (21.5) 16 (9.3) 0.002
Any adverse event
(including rash and
diarrhoea)*
46 (28.9) 27 (15.6) 0.004
Reported at day 10 n=135 n=151
Rash 2 (1.5) 10 (6.7) 0.04
Diarrhoea 17 (12.8) 8 (5.3) 0.04
Any adverse event
(including rash and
diarrhoea)*
19 (14.1) 19 (12.6) 0.73
A few patients on both follow-up days had missing data.
Figures are numbers of patients with an adverse reaction or event
(percentage).
*Other events were: admission to hospital, nausea or vomiting,
feeling light-headed or dizzy, lip swelling.
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publication. The principal reason for the unsupported
use of clindamycin in cellulitis is a widespread misunder-
standing of the natural history of the condition. The
local features of cellulitis will often progress (or at least
not improve) for several days after presentation. An
increasing affected area with mild fever and rising C
reactive protein leads both the patient and physician to
believe that the antibiotic treatment is failing; this is
despite the patient’s systemic symptoms of rigors, nausea
and anorexia improving. The addition of clindamycin or
change to intravenous therapy is consequently and spuri-
ously attributed as being responsible for the patient’s
improvement. The fact that 14 patients were intention-
ally given clindamycin and withdrawn from the trial is a
reﬂection of the belief in clindamycin’s powers. It is
probable that by the time the patient presents to a
healthcare professional with local signs of cellulitis, the
various toxins have bound to their targets and initiated
the exaggerated inﬂammatory response which is part of
the cause of skin damage. At this point, the Streptococcus
is replicating and susceptible to β-lactam antibiotics, or
no longer viable, so the addition of another antibiotic
will have no beneﬁcial effect. The mechanisms are
similar to those of envenoming,30 and it is unsurprising
that drugs thought to reduce toxin production given
days later are unlikely to be effective.
The Cochrane review of interventions in cellulitis
found no difference in outcome, however measured,
between treatment with a β-lactam versus either macro-
lides or streptogramin.10 A large trial comparing dicloxa-
cillin with clindamycin in the treatment of skin
infections found no difference in efﬁcacy.23 These
studies support the outcome of this trial because if toxin
inhibition was of importance, then the superiority of
clindamycin should have been evident.
This clinical trial has shown that adjunctive clindamy-
cin has no effect on improving outcome in cellulitis. Its
only real effect is increasing the likelihood of diarrhoea
with a rate comparable to that previously recorded.23 31
It is also likely that there is no beneﬁt in invasive GAS
disease. Any further use of adjunctive clindamycin and
other protein-inhibiting antibiotics, either concurrently
or sequentially, for the treatment of streptococcal and
staphylococcal infections should only be within a clinical
trial.
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